|
Video: What is a Stock Split?
|
|
Bone Biologics is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX®. The NELL-1/DBX® combination product is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The protein, as part of the UCB-1 technology platform has been licensed for worldwide applications to Co. through a technology transfer from UCLA Technology Development Group. Co.'s platform technology has application in delivering outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. According to our BBLG split history records, Bone Biologics has had 2 splits. | |
|
Bone Biologics (BBLG) has 2 splits in our BBLG split history database. The first split for BBLG took place on June 07, 2023. This was a 1 for 30 reverse split, meaning for each 30 shares of BBLG owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 33.3333333333333 share position following the split. BBLG's second split took place on December 20, 2023. This was a 1 for 8 reverse split, meaning for each 8 shares of BBLG owned pre-split, the shareholder now owned 1 share. For example, a 33.3333333333333 share position pre-split, became a 4.16666666666667 share position following the split.
When a company such as Bone Biologics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the BBLG split history from start to finish, an original position size of 1000 shares would have turned into 4.16666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Bone Biologics shares, starting with a $10,000 purchase of BBLG, presented on a split-history-adjusted basis factoring in the complete BBLG split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/13/2021 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$1,221.60 |
|
End price/share: |
$1.53 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.87% |
|
Average Annual Total Return: |
-92.82% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$12.53 |
|
Years: |
2.54 |
|
|
|
Date |
Ratio |
06/07/2023 | 1 for 30 | 12/20/2023 | 1 for 8 |
|
|